Media Articles Related to Fareston (Toremifene)
SHAVE a Big Plus in Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2015.05.22]
Dr Kathy Miller makes her top picks of breast cancer studies to watch at ASCO, noting trials in ER-positive and HER2-positive disease--and a small surgical study that may yield big benefits.
Family history has 'no adverse effect' on breast cancer outcomes
Source: Anxiety / Stress News From Medical News Today [2015.05.20]
Women diagnosed and treated for breast cancer under the age of 41 have an outlook just as good with family history of the disease as without - with similar prognosis of recurrence.
A blood test for early detection of breast cancer metastasis
Source: Breast Cancer News From Medical News Today [2015.05.18]
Research findings from Lund University in Sweden now provide new hope for a way of detecting metastases significantly earlier than is currently possible.
siRNA-toting nanoparticles inhibit breast cancer metastasis
Source: Breast Cancer News From Medical News Today [2015.05.15]
Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.
Women with inherited KRAS-variant mutation may be at increased breast cancer risk due to acute estrogen withdrawal
Source: Breast Cancer News From Medical News Today [2015.05.14]
UCLA researchers have discovered that for women with a relatively common inherited mutation, known as the KRAS-variant, abrupt lowering of estrogen may increase their breast cancer risk and impact...
Published Studies Related to Fareston (Toremifene)
Prostate cancer diagnosis among men with isolated high-grade intraepithelial
neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral
high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy... CONCLUSION: Although toremifene 20 mg did not lower the PCa detection rate, men
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy
for prostate cancer. 
therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral
Toremifene decreases vertebral fractures in men younger than 80 years receiving
androgen deprivation therapy for prostate cancer. 
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.
Clinical Trials Related to Fareston (Toremifene)
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29,
and will continue to compare combined hormonal therapy using the experimental aromatase
inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene
(FarestonŽ), to the single agent FDA-approved aromatase inhibitor letrozole (FemaraŽ) for the
treatment of advanced breast cancer. The purpose of this study is to determine whether
maximal estrogen suppression achieved via the combination of atamestane, plus toremifene
(FarestonŽ), is more effective than letrozole (FemaraŽ) in delaying the growth of breast
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [Terminated]
The purpose of this study is to determine whether maximal estrogen suppression achieved via
the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene
(FarestonŽ), is more effective than another approved drug, letrozole (FemaraŽ), in delaying
the growth of breast cancer, and whether the side effects of the combined hormonal therapy
are different from the side effects of letrozole.
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Active, not recruiting]
The purpose of this study is to determine the effect of toremifene treatment to the MRI
findings of the breast in women suffering from premenstrual mastalgia.
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer [Not yet recruiting]
The purpose of this study is to determine whether Toremifene Citrate is effective in
reducing the risk of bone fractures in men with prostate cancer who are on Androgen
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer [Recruiting]
Reports of Suspected Fareston (Toremifene) Side Effects
Hepatic Function Abnormal (4),
White Blood Cell Count Decreased (4),
Interstitial Lung Disease (3),
Hepatitis Acute (2),
Condition Aggravated (2),
Respiratory Failure (2),
Neoplasm Progression (1),
Osteomyelitis (1), more >>